Plain-English translation of NCT05763277 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
This trial is testing how well atezolizumab-bevacizumab works as a treatment for advanced liver cancer and trying to figure out early signs of whether the medication is helping. The researchers want to build a prediction tool that can tell patients and doctors, early in treatment, whether this medication is going to be effective for them.
While this medication has been shown to work better than older treatments for advanced liver cancer, doctors don't yet have a reliable way to know early on who will respond well to the treatment. This study aims to fill that gap by identifying early warning signs that can predict treatment success.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
As a participant, you would receive the medication as part of your regular cancer treatment plan. The study would track how your body responds to the treatment using medical imaging and other tests that your doctors would typically do anyway to monitor your progress. Researchers will use this information to develop an early prediction model to help future patients.
AI-generated summary from trial data ยท Jun 13, 2026 ยท Not medical advice
South Korea
Enrollment target
~170 participants
Started
July 2022
Primary completion
December 2025
This trial's estimated completion date has passed โ the record may not be fully up to date.
Age range
18 Years โ 80 Years
Last updated on clinicaltrials.gov in May 2025.
Reach out to the team running this trial. Response times vary โ some teams are faster than others.
Central contact
Jeong-Hoon Lee, MD PhD
Seoul National University Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first โ no email needed to get started.